GNC Proteins for Multi-Specific T-Cell Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as monoclonal antibodies and CAR-T therapy, face challenges in effectively targeting and overcoming immune evasion mechanisms of tumors, particularly in patients with low tumor mutational load, and managing adverse effects like cytokine release syndrome.
Innovation Solution
Development of Guidance and Navigation Control (GNC) proteins with multi-specific antigen binding activities, comprising cytotoxic cell binding moieties and cancer-targeting moieties, to redirect and activate T cells to tumor cells, modulating immune response through simultaneous binding to multiple surface molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies or CAR-T therapy are used to target tumor cells, then immune recognition of cancer cells is improved, but the ability to overcome immune evasion mechanisms in patients with low tumor mutational load is insufficient
Solution Approach 1:
The patent applies multi-specific binding proteins that can simultaneously bind to multiple different antigens on tumor cells and immune cells. This multi-functionality allows a single therapeutic agent to work across different cancer types and immune evasion mechanisms, rather than requiring separate monoclonal antibodies for each target. The proteins can engage T cells, NK cells, and macrophages while targeting multiple tumor antigens simultaneously, providing universal activity against diverse tumors including those with low mutational load.
Solution Approach 2:
The patent combines multiple binding specificities into single protein molecules, merging the functions of several monoclonal antibodies or CAR-T receptors into one agent. These multi-specific proteins can simultaneously engage multiple immune cell types and target multiple tumor antigens, consolidating what would otherwise require multiple separate therapies into a single unified treatment approach that overcomes immune evasion more effectively.
2Reliability
If combination therapy with multiple monoclonal antibodies is used to treat cancer, then overall survival and progression-free survival are improved, but treatment complexity and cost increase
Solution Approach 1:
The patent merges multiple antibody functions into single multi-specific binding proteins that can simultaneously target multiple antigens and engage multiple immune cell types. This consolidation reduces the complexity of combination therapies by replacing multiple separate monoclonal antibody infusions with a single multi-specific agent that provides comparable or superior efficacy through its ability to engage multiple immune pathways simultaneously.
Solution Approach 2:
The multi-specific binding proteins serve multiple therapeutic functions in a single molecule, including tumor antigen targeting, T cell engagement, NK cell activation, and macrophage modulation. This multi-functionality eliminates the need for complex combination regimens of separate monoclonal antibodies, simplifying treatment protocols while maintaining or improving survival outcomes through coordinated multi-pathway engagement.
3Power
If CAR-T therapy is used to target tumor cells, then T cell activation and tumor killing are enhanced, but adverse effects like cytokine release syndrome increase
Solution Approach 1:
The patent employs multi-specific binding proteins that can selectively engage different immune cell types with different binding specificities, allowing localized and controlled activation of cytotoxic functions. Rather than uniformly activating all T cells systemically (which causes cytokine release syndrome), the proteins can target specific tumor-associated antigens and engage specific immune subsets at the tumor site, providing controlled local cytotoxicity with reduced systemic adverse effects.
Solution Approach 2:
The multi-specific binding proteins provide dynamic and adjustable immune engagement, where the degree and type of immune activation can be modulated by the presence of different antigens on tumor cells. This dynamic engagement allows the therapy to adapt its cytotoxic power to the specific tumor context, activating sufficient T cell and NK cell responses to kill tumors while avoiding excessive systemic activation that leads to cytokine release syndrome.
Data Source
AI summary
The application provides guidance and navigation control (GNC) proteins. In one embodiment, the GNC protein Comprises a T-cell binding moiety and a cancer-targeting moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the cancer targeting moiety has a binding specificity to a cancer cell receptor.